



Commentary Murthystations and 90% had 10 or more nodes removed from 3 mediasti-
nal lymph node stations.
Dr Zielinski. My second question is, do you know how many
patients were positive on the initial sampling with frozen-section?
Dr Darling. We don’t have that data because they were not
eligible to be randomized.
Dr Paul De Leyn (Leuven, Belgium). That was a nice presenta-
tion. When you read the article in 2005, which describes morbidity
and mortality, you indeed think that the sampling is already exten-
sive, and this is important. Can you describe from a technical point
of viewwhen you sample, let’s say, station 7, is this just picking out
a few nodes or is this removing this whole station? What is the dif-
ference between sampling and dissection in your study?COMMEN
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670 The Journal of Thoracic and Cardiovascular SurgDrDarling.The sampling protocol specified that you were sim-
ply directed to sample one node from each station. If there were
any suspicious-looking nodes, obviously they were also required
to be sampled as opposed to doing a formal clean-out of the
area. So the protocol did specify to sample 1 node. Occasionally
the surgeons would take more than 1 node, but, as I mentioned,
if they took a whole lot of nodes (eg, 5–7 nodes from station 7),
we disqualified those as being a dissection rather than a sampling.
For the lymph node dissection, the protocol specified removing all
lymph node-bearing tissues between anatomic boundaries. For ex-
ample, for stations 2R and 4R all tissue between the superior vena
cava, trachea, right innominate artery, and the right bronchus was
removed, not just the visible lymph nodes.TARYLess is more. (more or less.)Sudish C. Murthy, MD, PhDIn this month’s issue, Dr Darling and colleagues present the
results of a long-awaited multicenter, prospective, random-
ized trial comparing efficacy of mediastinal lymph node
sampling (MLNS) and mediastinal lymph node dissection
(MLND) for localized non–small cell lung cancer (NSCLC).
This study was one of the many ‘‘brain-children’’ of the late
Dr Robert J. Ginsberg, and its organization, attention to de-
tail, and insight speak to the lasting legacy of this pioneer. In
addition, the group of distinguished authors who carried this
trial to its conclusion has overcome enormous obstacles to
complete this ambitious enterprise, dutifully and meticu-
lously organizing data collected from over 100 surgeons at
63 member institutions while maintaining some element
of quality control throughout the process—truly a formida-
ble task whose complexity should be appreciated.
The importance of this trial cannot be underestimated in-
asmuch as the role of lymphadenectomy for NSCLC, until
now, has served as a point of confusion for most thoracicsurgical oncologists. Although widely heralded as an im-
portant adjunct for management of the disease, there has
been little evidence to support this grandiose contention
in clinical practice. In fact, a shockingly high number of
lung cancer operations are performed without a single me-
diastinal lymph node even being sampled.1 Yet, despite this,
sophisticated and detailed guidelines of howMLND should
be integrated into NSCLC management have continued to
emerge.2 At last, there is a well-done, randomized trial to
support a position on the subject.
The findings of this trial are provocative, as surprisingly,
equivalence was found between MLNS and MLND for pa-
tients with early NSCLC (N0 or nonhilar N1 cancers). This,
in part, corroborates results from a similar, albeit much
smaller and less well-controlled, trial from a decade ago.3
But the results appear to fly against the popular notion
that MLND is a superior surgical technique with important
survival benefits for patients with early-stage NSCLC.4-7
None of these lesser studies was randomized or as well
conceived, however. Importantly, after careful review of
each study, including my own, unfortunately, the authors
of the latter group of manuscripts need not ready their
retraction statements just yet, inasmuch as there may still
be room for peaceful coexistence between studies,
because slightly different questions were addressed by each.
There is a reason why such randomized studies are com-
pleted so infrequently and why this trial casts such a heroic
specter. Clearly, it is difficult to have equipoise for such




Murthy Commentaryand that the authors were able to enlist so many qualified
surgeons speaks to their diligence and perseverance, no
doubt. In addition, data organization and institutional re-
view board clearance at each institute are time and resource
consumers. Perhaps most important of all is that, unlike ran-
domized chemotherapy trials for NSCLC, where drug type,
dose, mechanism of delivery, and infusion timing can be
easily standardized, this trial involved the performance of
two specific techniques by 102 different surgeons, hardly
a model to guarantee reproducibility.
The lead investigators provided guidelines and an in-
structional video to the participants and have dutifully re-
viewed pathology reports from member institutes, but that
is the extent of their standardization. They did use a reason-
able surrogate as a quality index (number of lymph nodes
resected), although I would challenge any pathologist to dif-
ferentiate between fragments of lymph nodes and actual
number, and any surgeon to extract each lymph node en
bloc for his or her pathologists to faithfully count. I suspect
that volumetric or mass assessment of resected lymphatic
tissues might have made for a stronger surrogate from
a quantitative standpoint, but those data were unavailable.
Even the lesser of these two procedures, MLNS, provides
staging information perhaps of an order of magnitude
greater than that which traditionally accompanies a standard
lung cancer resection performed in this country.1 The as-
sumption that all of us must make is that MLNS is still
just sampling and is distinct from MLND, which must
more closely approximate an exenteration. However, one
can easily imagine a vigorous sampling by one surgeon con-
sidered a passable lymphadenectomy by another, and vice
versa. Consequently, the possibility is raised that the two
treatment arms are similar enough to be statistically indis-
tinguishable and hence explain the negative trial. Instead
of comparing apples to oranges, the comparison becomes
apples to apples, perhaps Macintosh to Red Delicious,
where even the trained palate may have difficulty discerning
between the two.
In their defense, the authors demonstrate that, on average,
18 more lymph nodes were resected in the MLND group.
But whether this represents 18 more fragments from already
well-sampled lymph nodes or 18 novel mediastinal/hilar
lymph nodes is impossible to speculate. That the authors
did remove some patients from the trial who they believed
were too vigorously sampled or weakly dissected suggests
that this limitation was not ignored, and the investigators
were making every attempt to navigate safely down this
slippery slope.
I, for one, believe that Dr Darling and her colleagues got
it right—that MLNS was sampling and that MLND was
a more complete lymphadenectomy, and that the two have
an identical impact on survival and recurrence for patients
with well-staged early cancers. After all, why should lung
cancer behave any differently from most other solid-organThe Journal of Thoracic and Cacancers for which regional lymphadenectomy is becoming
an increasingly marginalized technique?8-12
Moreover, these findings should ease lingering concerns
that lesser operations for early-stage cancer (video-assisted
thorascoscopic surgery) are inferior from an oncologic
standpoint because fewer lymph nodes are interrogated13
and, instead, redirect efforts toward determining how much
MLNS is sufficient for a case to be considered well staged.
Are a few needle passes with ultrasound guidance through
a bronchoscope enough? Algorithms are already being de-
vised using existing complementary staging techniques to
simplify care and reduce costs and morbidity, and until
now, it was hard to adopt such because one had to believe
without knowing that less really might be more.
The authors conclude on a bit of a curious note. Despite
the compelling data that were presented and the apparent in-
controvertible finding that was rendered, the article endswith
the recommendation that MLND still be performed for re-
sectable NSCLC because it does not increase morbidity or
mortality and remains the most accurateway to stage the dis-
ease, points proudly made in some of those nearly retracted
studies from above. It is almost as if MLND is reaching out
from the grave, still refusing to go quietly into the night. Per-
haps their intentions are to remind us not to put all our eggs
into MLNS. Their results, though, suggest we should.
So what does MLND really offer? As demonstrated in
this trial, it identifies 4% of patients who would have other-
wise had unsuspected N2 disease if only treated by MLNS
(stage IIIA/B). They would almost certainly have been
offered adjuvant chemotherapy if properly identified, and
perhaps 10% to 15% of them would have been cured.
That is a 0.5% potential salvage rate, and for a study of
this size, it translates into 2 patients who may have been
cured if they had received MLND instead of MLNS. Is
this really worth the hedge? Surely there must be more
sophisticated and intelligent mechanisms (proteomics and
genomics) than MLND to identify these needles in our
haystacks.
Regardless, it is a terrific study performed by a group of
scholarly thoracic surgeons and should immediately affect
surgical management of lung cancer by relegation of
MLND to highly selected instances. The finding of equiva-
lence does not make this a negative trial. On the contrary,
there is absolutely nothing negative about the trial. It was
simply constructed well enough that any result, including
equivalence, would be important.
To end where much of this began, we can retreat back-
ward about a decade and a half. In his review from then,
Dr Ginsberg14 wrote: ‘‘The addition of mediastinal lymph
node dissection produces the best possible surgical and
pathologic staging of lymph node disease but has yet to
be proven more efficacious as a curative procedure.’’
Finally, after these many years, I think it can be stated




Commentary Murthythat MLND is not more efficacious and, indeed, it does
appear that less is more.more or less.
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